Abstract

BackgroundSomatic mutations affecting components of the RNA splicing machinery occur with high frequencies across many tumor types. These mutations give rise to distinct alterations in normal splice site and exon recognition, such as unusual 3′ splice site preferences, that likely contribute to tumorigenesis.MethodsWe analyzed genome-wide patterns of RNA splicing across 805 matched tumor and normal control samples from 16 distinct cancer types to identify signals of abnormal cancer-associated splicing.ResultsWe found that abnormal RNA splicing, typified by widespread intron retention, is common across cancers even in the absence of mutations directly affecting the RNA splicing machinery. Almost all liquid and solid cancer types exhibited frequent retention of both alternative and constitutive introns relative to control normal tissues. The sole exception was breast cancer, where intron retention typified adjacent normal rather than cancer tissue. Different introns were preferentially retained in specific cancer types, although a small subset of introns enriched for genes encoding RNA splicing and export factors exhibited frequent retention across diverse cancers. The extent of intron retention correlated with the presence of IDH1 and IDH2 mutations in acute myeloid leukemia and across molecular subtypes in breast cancer. Many introns that were preferentially retained in primary cancers were present at high levels in the cytoplasmic mRNA pools of cancer cell lines.ConclusionsOur data indicate that abnormal RNA splicing is a common characteristic of cancers even in the absence of mutational insults to the splicing machinery, and suggest that intron-containing mRNAs contribute to the transcriptional diversity of many cancers.

Highlights

  • Somatic mutations affecting components of the RNA splicing machinery occur with high frequencies across many tumor types

  • Small molecules that inhibit splicing have antitumor activity [15, 16]; the SF3b component PHF5A is differentially required for constitutive splicing in glioblastoma versus normal neural stem cells [17]; RNA splicing is reportedly noisier in cancers than normal cells [18]; increased intron retention is associated with SETD2 mutations in kidney cancer [19] and castration resistance in prostate cancer [20]

  • Our results indicate that intron retention is a common correlate of tumorigenesis, and suggest that an abundance of intron-containing mRNAs in cancer cells may increase the diversity of many cancer transcriptomes

Read more

Summary

Introduction

Somatic mutations affecting components of the RNA splicing machinery occur with high frequencies across many tumor types. Small molecules that inhibit splicing have antitumor activity [15, 16]; the SF3b component PHF5A is differentially required for constitutive splicing in glioblastoma versus normal neural stem cells [17]; RNA splicing is reportedly noisier in cancers than normal cells [18]; increased intron retention is associated with SETD2 mutations in kidney cancer [19] and castration resistance in prostate cancer [20] These and other studies together suggest that common RNA processing differences may distinguish cancer and normal cells irrespective of tissue of origin.

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call